Lisata Therapeutics, a leading pharmaceutical company, has reached significant regulatory achievements pertaining to their innovative drug candidates, certepetide for pancreatic cancer and LSTA1 for osteosarcoma. The European Medicines Agency (EMA) has recently granted Lisata Therapeutics a Paediatric Investigation Plan (PIP) waiver for certepetide, confirming that paediatric studies for pancreatic cancer are not required. Additionally, the United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to LSTA1, marking a critical first step towards priority review voucher acquisition.
Certepetide and Pancreatic Cancer
Lisata Therapeutics’ drug candidate, certepetide, has shown promising potential for the treatment of pancreatic cancer. The company’s application for a PIP waiver from the EMA has been successful, signifying that conducting paediatric studies for this particular indication is deemed unnecessary. This waiver supports the notion that certepetide is not intended for paediatric use and allows Lisata Therapeutics to focus solely on adult patients with pancreatic cancer. This regulatory milestone underscores the confidence of regulatory authorities in the drug’s safety and efficacy for the intended patient population.
LSTA1 and Osteosarcoma
Lisata Therapeutics has also achieved a significant regulatory milestone with their drug candidate, LSTA1, in the treatment of osteosarcoma. The FDA has granted Rare Pediatric Disease Designation for LSTA1, marking an important initial step towards a potential priority review voucher. This designation is granted to drug candidates that address rare diseases affecting children and provides incentives to pharmaceutical companies to develop such therapies. Lisata Therapeutics’ achievement of this designation for LSTA1 highlights the drug’s potential to address the pressing medical needs of paediatric osteosarcoma patients.
Conclusion:
Lisata Therapeutics, a pioneering pharmaceutical company, has made significant strides in securing regulatory milestones for their drug candidates, certepetide and LSTA1. The recent PIP waiver from the EMA for certepetide in pancreatic cancer affirms that paediatric studies are not necessary, allowing the company to focus exclusively on adult patients. Additionally, the FDA’s Rare Pediatric Disease Designation for LSTA1 in osteosarcoma represents a critical initial step towards priority review voucher acquisition. These achievements highlight Lisata Therapeutics’ commitment to advancing innovative therapies and addressing unmet medical needs.
Comments